A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019A in Patients With Relapsed/Refractory Multiple Myeloma.

This is a single-arm, open-label, single-center clinical trial to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of QI-019A in patients with relapsed/refractory multiple myeloma.

Trial Details

NCT ID
NCT07429721
Phase
EARLY_PHASE1
Sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • QI-019A Injection
Locations (sample)
  • Wuhan, Hubei, China|30.58333,114.26667

Key Eligibility Criteria

  • 1\. Age ≥ 18 years, any gender;
  • 2\. Diagnosed with multiple myeloma (MM) according to IMWG diagnostic criteria;
  • 3\. Have received at least 2 lines of anti-MM treatment, with at least one full treatment cycle per line, and experienced disease progression durin…
  • 4\. Disease must be measurable at screening, meeting one or more of the following criteria:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →